Search for content, post, videos

Targovax completes 70 MNOK financing

Immunotherapy specialist Targovax has completed a 70 MNOK financing, mainly from new investors.

CEO Hanne M Kristensen states; “The capital increase of 70 MNOK will make us able to continue developing Targovax’s pipeline of immunotherapies targeting RAS mutated cancer forms, and also gives us a strong position to develop Targovax as a company”.

Chairman Jónas Einarsson comments; “This is an important step forward for Targovax, and clearly shows that the Norwegian investment community has opened its eyes to our sector.”

Datum and partners represent the largest new group of shareholders.